JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

Klimik Journal is a pivotal publication in the fields of Infectious Diseases and Medical Microbiology, serving as a platform for researchers, clinicians, and academics to disseminate groundbreaking findings and improve health outcomes. Established in 2010 and published by DOC DESIGN INFORMATICS CO LTD, this journal is dedicated to advancing knowledge and fostering discussions around critical issues in infectious diseases and microbial research. With an ISSN of 1301-143X and an E-ISSN of 1309-1484, Klimik Journal strives to maintain high academic standards despite currently ranking in the fourth quartile in both categories according to Scopus metrics, which highlights the need for continued contributions to the field. Operating from Turkey, the journal is committed to supporting open access options, thereby ensuring wide dissemination of research findings. As it continues to bridge the gap between theory and practice, Klimik Journal is poised to become an essential resource for those looking to stay at the forefront of infectious disease research and microbiological advancements.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Reviews and Research in Medical Microbiology is a premier academic journal published by LIPPINCOTT WILLIAMS & WILKINS, focusing on groundbreaking research and comprehensive reviews that advance the understanding of medical microbiology. With an ISSN of 2770-3150 and an E-ISSN of 2770-3169, this journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of pathogens, infectious diseases, and microbial mechanisms affecting health. While the journal currently does not offer open access, its rigorous peer-review process ensures that only high-quality, impactful research is disseminated to the scientific community. The journal aims to bridge gaps in knowledge by presenting cutting-edge studies that explore novel therapeutic strategies, diagnostic methods, and the evolving landscape of microbial resistance. Nestled in the heart of Philadelphia, this journal proudly contributes to the advancement of medical microbiology and is an indispensable platform for the publication of critical findings that shape clinical practices and research trajectories in the field.

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.